透析療法ネクスト　XIII

出版社： 医学図書出版
著者：
発行日： 2012-07-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784871514354
電子書籍版： 2012-07-01
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

新時代の高リン血症治療について。

目次

  • 透析療法ネクスト　XIII

    ―目次―

    座談会
    　厳格なリン管理は何をもたらすか

    特集　新時代の高リン血症治療
    　透析患者の栄養とリン代謝
    　リン管理の意義とその現況
    　CKD-MBD治療ガイドラインにみる高リン血症治療
    　リン吸着薬としての炭酸ランタンの長期効果
    　炭酸ランタン：血管石灰化抑制は可能か　
    　炭酸ランタン：骨代謝への期待
    　腹膜透析患者における高リン血症治療
    　リン吸着薬の適正使用〜炭酸ランタンは安全か？〜　
    　炭酸ランタンとビタミンD治療　　
    　炭酸ランタンとX線検査　　　
    　これからの高リン血症治療薬　
    　透析療法の歴史（13）―腎性骨症からCKD-MBDへ（その1）―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

座談会

P.10 掲載の参考文献
1) de Boer IH, Rue TC, Kestenbaum B : Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 53 : 399-407, 2009
PubMed
2) Ring T, Sanden AK, Hansen HH, et al : Ultradian variation in serum phosphate concentration in patients on haemodialysis. Nephrol Dial Transplant : 59-63, 1995
PubMed

特集 新時代の高リン血症治療

P.19 掲載の参考文献
1) Kalantar-Zadeh K, Kopple JD : Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 38 : 1343-1350, 2001
PubMed
2) Stenvinkel P, Heimburger O, Paultre F, et al : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 : 1899-1911, 1999
PubMed
3) Fouque D, Kalantar-Zadeh K, KoPPIe J, et al : A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73 : 391-398, 2008
 
4) Fouque D, Pelletier S, Mafra D, et al : Nutrition and chronic kidney disease. Kidney Int 80 : 348-357, 2011
PubMed
5) Hruska KA, Mathew S, Lund R, et al : Hyperphosphatemia of chronic kidney disease. Kidney Int 74 : 148-157, 2008
PubMed
6) Miyamoto K, Haito-Sugino S, Kuwahara S, et al : Sodium-dependent phosphate cotransporters : lessons from gene knockout and mutation studies. J Pharm Sci 100 : 3719-3730, 2011, Review
PubMed
7) Razzaque MS : FGF23-mediated regulation of systemic phosphate homeostasis : is Klotho an essential player? Am J Physiol Renal Physiol 296 : F470-F476, 2009
PubMed
8) Isakova T, WahlP, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011
 
9) Kalantar-Zadeh K, Gutekunst K, Mehrotra R, et al : Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 5 : 519-530, 2010
 
10) National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 [Suppl 3］ : S1-S201, 2003
 
11) Shinaberger CS, Greenkand S, KopPle JD, et al : Is controlling Phosphorus by decreasing dietary protein intake beneticial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88 : 1511-1518, 2008
PubMed
P.26 掲載の参考文献
1) ADHR Consortium : Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26 : 345-348, 2000
PubMed
2) Liu S, Vierthaler L, Tang W, et al : FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19 : 2342-2350, 2008
PubMed
3) Larsson T, Nisbeth U, Ljunggren O, et al : Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 : 2272-2279, 2003
 
4) Maschio G, Tessitore N, D'Angelo A, et al : Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy. Am J Clin Nutr 33 : 1546-1554, 1980
PubMed
5) Alfrey AC : Effect of dietary phosphate restriction on renal function and deterioration. Am J Clin Nutr 47 : 153-156, 1988
PubMed
6) Wolf M : Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21 : 1427-1435, 2010
PubMed
7) Faul C, Amaral AP, Oskouei B, et al : FGF23 induces left ventricular hypertrophy. J Clin Invest 121 : 4393-4408, 2011
PubMed
8) Lowrie EG, Lew NL : Death risk in hemodialysis patients : the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 : 458-482, 1990
 
9) Leggat JE Jr., Orzol SM, Hulbert-Shearon TE, et al : Noncompliance in hemodialysis : predictors and survival analysis. Am J Kidney Dis 32 : 139-145, 1998
PubMed
10) Block GA, Hulbert-Shearon TE, Levin NW et al : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
PubMed
11) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
12) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006
PubMed
13) Nakai S, Akiba T, Kazama J, et al : Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12 : 49-54, 2008
PubMed
14) Mai ML, Emmett M, Sheikh MS, et al : Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36 : 690-695, 1989
PubMed
15) Ring T, Nielsen C, Andersen SP, et al : Calcium acetate versus calcium carbonate as phosphorus binders in patients on chronic haemodialysis : a controlled study. Nephrol Dial Transplant 8 : 341-346, 1993
PubMed
16) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
PubMed
17) London GM, Marchais SJ, Guerin AP, et al : Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 19 : 1827-1835, 2008
 
18) Chertow GM, Burke SK, Raggi P : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
PubMed
19) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
20) Qunibi W, Moustafa M, Muenz LR, et al : A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control : the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51 : 952-965, 2008
PubMed
21) Barreto DV, Barreto FC, de Carvalho AB, et al : Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 110 : c273-283, 2008
 
22) Suki WN, Zabaneh R, Cangiano JL, et al : Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 : 1130-1137, 2007
PubMed
23) Hutchison AJ, Laville M : Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 23 : 3677-3684, 2008
PubMed
24) Shigematsu T : Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70 : 404-410, 2008
 
25) Freemont AJ, Hoyland JA, Denton J : The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64 : 428-437, 2005
 
26) Toussaint ND, Lau KK, Polkinghorne KR, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis : A pilot randomized controlled trial. Nephrology (Carlton) 16 : 290-298, 2011
PubMed
27) Wilson R, Zhang P, Smyth M, et al : Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 25 : 3021-3028, 2009
 
28) Goto S, Komaba H, Moriwaki K, et al : Clinical eihcacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 6 : 1375-1384, 2011
PubMed
P.33 掲載の参考文献
1) Moe S, et al : Definition, evaluation, and classification of renal osteodystrophy : A position statement from Kidney Disease : Improving Global Outcomes (KDIGO) Kidney Int 69 : 1945-1953, 2006
PubMed
2) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
3) Massry SG, et al : K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Disease 42 : suppl 3 i-S201, 2003
 
4) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 76 : suppl 113 s1-130, 2009
 
5) Fukagawa M, Yumita S, Akizawa T, et al ; and KRN1493 study group : Cinacalcet effectively decreases The serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. NDT Advance Access published on August 23, 2007
 
6) Komaba H, Moriwaki K, Kamae I, et al : Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan Ther Apher Dial 13 (Suppl 1), S28-35, 2009
 
7) Kakuta T, Tanaka R, Fukagawa M, et al ; Effect of Sevelamer and Calcium-Based Phosphate Binders on Coronary Artery Calcification and Accumulation of Circulating Advanced Glycation End Products in Hemodialysis Patients. Am J Kidney Dis 57 : 422-431, 2011
PubMed
P.37 掲載の参考文献
1) Jono S, Mckee MD, Murry CE, et al : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000
PubMed
2) Block GA, Hulbert Shearon TE, Levin NW, et al : Associaion of serum phosphorus and calcium×phosphate product with mortality risk in chronic hemodialysis patients : a national study. Am J Kidney Dis 31 : 607-617, 1998
 
3) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
4) Nakai S, Akiba T, Kazama J, et al : Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12 : 49-54, 2008
PubMed
5) 重松隆 : リンバランスと塩酸セベラマー. 日本透析会誌 37 : 2055-2056, 2004
 
6) Hutchison AJ, Barnett ME, Krause R, et al : Long-term eihcacy and safety profile of lanthanum carbonate : results for up to 6 years of treatment. Nephron Clin Pract 110 : c15-c23, 2008
PubMed
7) Hutchison AJ, Maes B, Vanwalleghem J, et al : Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia : a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 100 : c8-c19, 2005
PubMed
8) D'Haese PC, Spasovski GB, Sikole A, et al : A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 64 : S73-S78, 2003
 
9) Finn WF : Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia : safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65 : 191-202, 2006
PubMed
10) Finn WF, Joy MS : A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 21 : 657-664, 2005
 
11) Shigematsu T ; Lanthanum Carbonate Group : Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70 : 404-410, 2008
PubMed
12) Shigematsu T ; the Lanthanum Carbonate Research Group : One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 14 : 12-19, 2010
 
13) Shigematsu T ; the Lanthanum Carbonate Research Group : Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol 14 : 589-597, 2010
 
P.42 掲載の参考文献
1) Kestenbaum B, Sampson JN, Rudser KD, et al : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005
PubMed
2) Eddington H, Hoefield R, Sinha S, et al : Serum Phosphate and Mortality in Patients with Chronic Kidney Disease. Clin J Am Soc Nephrol 5 : 2251-2257, 2010
PubMed
3) Block GA, Klassen PS, Lazarus JM, et al : Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
4) Jono S, McKee MD, Murry CE, et al : Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 : E10-17, 2000
PubMed
5) Fitzpatrick LA, Turner RT, Ritman ER : Endochondral bone formation in the heart : a possible mechanism of coronary calcification. Endocrinology l44 : 2214-2219, 2003
 
6) 塩井淳 : 血管壁の石灰化. Clinical Calcium 14 : 38-41, 2004
 
7) Zhou YB, Jin SJ, Cai Y, et al : Lanthanum acetate inhibits vascular calcification induced by vitamin D3 plus nicotine in rats. Exp Biol Med (Maywood) 234 : 908-917, 2009
PubMed
8) Neven E, Dams G, Postnov A, et al : Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 24 : 1790-1799, 2009
PubMed
9) Hoenderop JG, Van Der Kemp AW, Hartog A, et al : Molecular identification of the apical Ca2+ channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J Biol Chem 274 : 8375-8378, 1999
PubMed
10) Nikolov IG, Joki N, Nguyen-Khoa T, et al : Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 27 : 505-513, 2012
PubMed
11) Toussaint ND, Lau KK, Polkinghorne KR, et al : Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis : A pilot randomized controlled trial. Nephrology (Carlton) 16 : 290-298, 2011
PubMed
12) Kalil RS, Flanigan MG, Stanford W, et al : The effect of lanthanum carbonate (Fosrenol) on coronary artery calcification and endothelial function in hemodialysis patients, A pilot, prospective study. J Am Soc Nephrol 20 : 399A (abstract), 2009
 
P.48 掲載の参考文献
1) Saydah S, Eberhardt M, Rios-Burrows N, et al : Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004. JAMA 297 : 1767-1768, 2007
 
2) Kestenbaum B, Sampson JN, Rudser KD, et al : Serum phosphate levels and mortality among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005
PubMed
3) Moe SM, Zidehsarai MP, Chambers MA, et al : Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6 : 257-267, 2011
PubMed
4) Vervloet MG, van Ittersum FJ, Btittler RM, et al : Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 6 : 383-389, 2011
 
5) Slatopolsky E, Finch J, Denda M, et al : Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97 : 2534-2540, 1996
PubMed
6) Malluche HH, Mawad HW, Monier-Faugere MC : Renal osteodystrophy in the first decade of the new millennium : analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26 : 1368-1376, 2011
PubMed
7) Qing H, Ardeshirpour L, Dusevich V, et al : Osteocyte perilacunar remodeling is regulated hormonally, but not by mechanical unloading. J Bone Miner Res 24 Suppl : A09001496, 2009
 
8) Qing H, Ardeshirpour L, Pajevic PD, et al : Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res, Epub ahead of print 2012
 
9) Yajima A, Inaba M, Tominaga Y, et al : Increased osteocyte death and mineralization inside bone after parathyroidectomy for secondary hyperparathyroidism. J Bone Miner Res 25 : 2374-2381, 2010
PubMed
10) O'Brien CA, Plotkin LI, Galli C, et al : Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3 : e2942, 2008
PubMed
11) Bonewald LF : The amazing osteocyte, J Bone Miner Res 26 : 229-238, 2010
 
12) Nakashima T, Hayashi M, Fukunaga T, et al : Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17 : 1231-1234, 2011
PubMed
13) Slatopolsky E, Moe SM : 50 years of research and discovery in chronic kidney disease and mineral & bone disorder : the central role of phosphate. Kidney Int 79 (S121) : S1-S2, 2011
 
14) Moe SM : Vascular calcification : the threehit model. J Am Soc Nephrol 20 : 1162-1164, 2009
 
15) Moe SM, O'Neill KD, Duan D, et al : Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 : 638-647, 2002
PubMed
16) Chen NX, O'Neill KD, Moe SM : Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62 : 1724-1731, 2002
PubMed
17) Chen NX, Duan D, Moe SM : High glucose increases the expression of Cbfal and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant 21 : 3435-3442, 2006
 
18) Hyvarinen M, Tuomilehto J, Mahonen M, et al : DECODE Study Group. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. Stroke 40 : 1633-1637, 2009
 
19) Balkau B, Hu G, Qiao Q, et al ; DECODE Study Group : European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47 : 2118-2128, 2004
 
20) Alvarez JA, Ashraf AP, Hunter GR, et al : Serum 25-hydroxyvitamin D and parathyroid hormone are independent determinants of whole-body insulin sensitivity in women and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr 92 : 1344-1349, 2010
PubMed
21) Kamycheva E, Jorde R, Figenschau Y, et al : Insulin sensitivity in subjects with secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest 30 : 126-132, 2007
PubMed
22) Narisawa S, Harmey D, Yadav MC, et al : Novel inhibitor of alkaline phostatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 22 : 1700-1710, 2007
PubMed
23) Villa-Bellosta R, Wang X, Millan JL, et al : Extracellular pyrophosphate metabolism and calcification in vascular smooth muscle. Am J physiol Heart Circ Physiol 301 : H61-H68, 2011
PubMed
24) Hill K, Martin B, Moe SM, et al : Calcium carbonate supPlement produces positive calcium balance in stage 3/4 chronic kidney disease. J Bone Miner Res (Suppl) ; 26 : S184, 2011
 
25) Kakuta T, Tanaka R, Hyodo T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57 : 422-431, 2011
PubMed
26) Nikolov IG, Joki N, Nguyen-Khoa T, et al : Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2100, Epub ahead of print 2011
 
27) Hamano T, Matsui I, Mikami S, et al : Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21 : 1998-2007, 2010
PubMed
28) Aoshima Y, Mizobuchi M, Ogata H, et al : Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant 2012, Epub ahead of print
 
29) Moe SM, Seifert MF, Chen NX, et al : R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant 24 : 2371-2377, 2009
 
30) Hruska KA, Mathew S : Chronic kidney disease mineral bone disorder (CKD-MBD). In : Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 7th ed. Washington DC : American Society for Bone and Mineral Research, 343-349, 2008
 
31) Danese MD, Kim J, Doan QV, et al : PTH and the risks for hip, vertebral, and pelvic fractures among Patients on dialysis. Am J Kidney Dis 47 : 149-156, 2006
PubMed
32) Coco M, Rush H : Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36 : 1115-1121, 2000
PubMed
33) Rudsor KD, de Boer IH, Dooley A, et al : Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 18 : 2401-2407, 2007
 
34) Yajima A, Inaba M, Tominaga Y, et al : Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 74 : 775-781, 2008
PubMed
35) Yajima A, OgawaY, Takahashi HE, et al : Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 42 : 729-738, 2003
 
36) Pacifici R : Role of T cells in ovariectomy induced bone loss-Revisited. J Bone Miner Res 27 : 231-239, 2012
PubMed
37) Nakamura T, Imai Y, Matsumoto T, et al : Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 : 811-823, 2007
PubMed
38) Yajima A, Inaba M, Tominaga T, et al : Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol Dial Transplant 22 : 1645-1657, 2007
 
39) Seeman E, Delmas PD : Bone Quality-The material and structural basis of bone strength and fragility. N Engl J Med 354 : 2250-2261, 2006 (Review)
PubMed
40) Teti A, Zallone A : Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 44 : 11-16, 2009 (Review)
PubMed
41) Yoshiki Y, Wang H, Minamizawa T : Mineralized tissue cells are a principle of FGF23. Bone 40 : 1565-1573, 2007
 
42) Faul C, Amaral AP, Oskouei B, et al : FGF23 induces left ventricular hypertrophy, J Clin Invest 121 : 4393-4408, 2011
PubMed
43) Stubbs J, Liu S, Quarles LD : Regulation of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism. Semin Dial 20 : 302-308, 2007
PubMed
44) Pereira RC, JUpPner H, Azucena-Serrano CE, et al : Patterns of FGF-23, DMP-1, and MEPE expression in patients with chronic kidney disease. Bone 45 : 1161-1168, 2009
 
45) Wang H, Yoshiki Y, Yamamoto R, et al : Overexpression of fibroblast growth factor 23 differentiation and matrix in vitro. J Bone Miner Res 23 : 939-948, 2008
 
46) Imanishi Y, Hashimoto J, Ando W, et al : Matrix extracellular phosphoglucoprotein is expressed in cansative tumors of oncogenic osteomalacia. J Bone Miner Metab 30 : 93-99, 2012
PubMed
47) Quarles D : Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012, Epub ahead of print
 
48) Martin A, David V, Quarles LD l Relation and function of the FGF23/Klotho pathways. Physiol Rev 92 : 131-155, 2012
 
49) Feng JQ, Ward LM, Liu S, et al : Loss of DMP-1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38, 1310-1315, 2006
 
50) Tatsumi S, Ishii K, Amizuka N, et al : Targeted ablation of osteocytes induce osteoporosis with defective mechanotransduction. Cell Metab 5 : 464-475, 2007
PubMed
51) Paszty C, Turner CH, Robinson MK : Sclerostin : Agem from the genome leads to bone-building antibodies. J Bone Miner Res 25 : 1897-1904, 2010
 
52) Atkins GJ, Rowe PS, Lim HP, et al : Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res 26 : 1425-1436. 2011
PubMed
53) Wijenayaka AR, Kogawa M, Lim HP, et al : Sclerostin stimulates osteocyte supPort of osteoclast activity by a RANKL-dependent pathway. PLoS One 6 : e25900, Epub 2011
 
54) Rhee Y, Bivi N, Farrow E, et al : Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49 : 636-643, 2011
PubMed
55) Sato T, Tominaga Y, Ueki T, et al : Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44 : 481-487, 2004
PubMed
56) Tonelli M, Pannu N, Manns B : Oral phosphate binders in patients with kidney failure. N Engl J Med 362 : 1312-1324, 2010
PubMed
57) Splague SM, Abboud H, Qiu, et al : Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4 : a randomized trial. Clin J Am Soc Nephrol 4 : 178-185, 2009
 
58) Harrison TS, Scott LJ : Lanthanum carbonate. Drugs 64 : 985-996, 2004
 
59) Nikolv IG, Nguyen-Khoa T, Guerrera IC, et al : Lanthanum carbonate, like sevelamar-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein in E-deficient mice. Nephrol Dial Transplant 27 : 505-513, 2012
 
60) Shigematsu T, Negi S ; the COLC Research Group : Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrol Dial Transplant 27 : 1050-1054, 2012
 
61) Gonzalez-Parra E, Gonzales-Causus Maria, Galan A, et al : Lanthunum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 26 : 2567-2571, 2012
 
62) Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al : The parathyroid glands is a target organ for FGF23 in rats. J Clin Invest 117 : 557-559, 2007
 
63) Stubbs JR, He Nan, Idiculla A, et al : Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 27 : 38-46, 2012
 
64) Canalejo R, Canalejo A, Manual Martinez-Moreno J, et al : FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21 : 1125-1135, 2010
 
65) Krajisnik T, OLauson H, Mirza MA, et al : Parathyroid glands and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int 78 : 1024-1032, 2010
PubMed
66) Komaba H, Goto S, Fujii H, et al : Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 : 232-238, 2010
PubMed
67) Spasovski GB, Sikole A, Gelev S, et al : Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow up. Nephrol Dial Transplant 21 : 2217-2224, 2006
PubMed
68) Yajima A, Tanaka K, Tominaga Y, et al : Early changes of bone histology and circulating markers of bone turnover after parathyroidectomy in hemodialysis patients with severe hyperparathyroidism. Clin Nephrol 56 : 27-34, 2001
PubMed
69) Andress DL, Ott SM, Maloney NA, Sherrard DJ : Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 312 : 468-473, 1985
 
70) Rhee Y, Allen MR, Condon K, et al : PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res. 26 : 1035-1046, 2011
PubMed
71) Vertino AM, Bula CM, Chen JR, et al : Nongenotropic, anti-apoptotic signaling of 1alpha, 25 (OH) 2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J Biol Chem 280 : 14130-14137, 2005
PubMed
72) Malluche HH, Siami GA, Swanepoel C, et al : Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 70 : 284-295, 2008
PubMed
73) Shigematsu T, Tokumoto A, Nakaoka A, et al : Effect of lanthanum carbonate on bone in Japanese dialysis patients with hyperparathyroidism. Ther Apher Dial 12 : 55-61, 2010
 
74) Freemont AJ, Hayland JA, Denton J : Lanthanum Carbonate SPD405-303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 64 : 428-437, 2005
 
75) Damment S, Secker R, Shen R, et al : Longterm treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure. Nephrol Dial Transplant 26 : 1803-1812, 2011
 
P.64 掲載の参考文献
1) Moe S, Drueke T, Lameire N, et al : Chronic kidney disease-mineral-bone disorder : a new paradigm. Adv Chronic Kidney Dis 14 : 3-12, 2007
PubMed
2) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : improving Global Outcomes (K/DIGO). Kidney Int 69 : 1945-1953, 2006
 
3) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
4) Noordzji M, Korevaar JC, Bos WJ, et al : Mineral metabolism and cardiovascular morbidity and mortality risk : peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 21 : 2513-2520, 2006
 
5) 日本透析医学会 : わが国の慢性透析療法の現況 2010 (2009年12月31日末)
 
6) Llach F : Secondary hyperparathyroidism in renal failure : the trade-off hypothesis revisited. Am J Kidney Dis 25 : 663-679, 1995
PubMed
7) Komaba H, Kakuta T, Fukagawa M : Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 15 : 797-809, 2011
PubMed
8) Tokumoto M, Taniguchi M, Matsuo D, et al : Parathyroid cell growth in patients with advanced secondary hyperparathyroidism : vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther Apher Dial 9 : S27-S34, 2005
PubMed
9) Taniguchi M, Tokumoto M, Matsuo D, et al : Parathyroid gland growth and regression in experimental uremia. Kidney Int 69 : 464-470, 2006
PubMed
10) Coen G : Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease. Kidney Int 74 : 1229-1231, 2008
PubMed
11) Prie D, Urena TP, Friedlander G : Latest findings in phosphate homeostasis. Kidney Int 75 : 882-889, 2009
 
12) Isakova T, Wahl P, Vargas GS, et al : Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79 : 1370-1378, 2011
 
13) Kuro-o M : Phosphate and Klotho. Kidney Int 79 (Suppl 121) : S20-S23, 2011
PubMed
14) Yamamoto Y, Kasai K, Hamada C, et al : Differences in corrective mode for divalent ions and parathyroid hormone between standard and low-calcium dialysate in patients on continuous ambulatory peritoneal dialysis-result of a nationwide survey in Japan. Perit Dial Int 28 (Suppl 3) : S128-S130, 2008
 
15) Sprague SM, Evenepoel P, Curzi MP, et al : Simultaneous control of PTH and Ca×Ps sustained over three years of treatment with cinacalcet HCI. J Am Soc Nephrol 4 : 1465-1476, 2009
 
16) Hamada C, Hayashi K, Shou I, et al : Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysis bags in peritoneal dialysis patients. Perit Dial Int 25 : 570-575, 2005
PubMed
17) Wang AY, Woo J, Sea MM, et al : Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function : what are the implications? Am J Kidney Dis 43 : 712-720, 2004
PubMed
18) Tonelli M, Pannu N, Manns B : Oral phosphate binders in patients with kidney failure. N Engl J Med 362 : 1312-1324, 2010
PubMed
19) 重松隆 : リンバランスと塩酸セベラマー. 透析会誌 37 : 2055-2056, 2004
 
20) Rufino M, de Bonis E, Martin M, et al : Is it possible to control hyperphosphatemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 13 : 65-67, 1998
 
21) Shinaberer CS, Greenland S, Kopple JD, et al : Is controlling Phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88 : 1511-1518, 2008
PubMed
22) Moe SM, Zidehsarai MP, Chambers MA, et al : Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 6 : 257-264, 2011
PubMed
23) Messa P, Gropuzzo M, Cleva M, et al : Behavior of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 13 (Suppl 6) : 43-48, 1998
 
24) Kuhlmann MK : Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 29 : 137-144, 2010
PubMed
25) Sedlacek M, Dimaano F, Uribarri J : Relationship between phosphorus and creatinine clearance in peritoneal dialysis : clinical implications. Am J Kidney Dis 36 : 1020-1024, 2000
PubMed
26) Badve SV, Zimmerman DL, Knoll GA, et al : Peritoneal phosphate clearance is influenced by peritoneal dialysis modality, independent of peritoneal transport characteristics. Clin J Am Soc Nephrol 3 : 1711-1717, 2008
PubMed
27) Huchison AJ : Oral phosphate binders. Kidney Int 75 : 906-914, 2009
 
28) Daugirdas JT, Finn WF, Emmett M, et al : The phosphate binder equivalent dose. Semin Dial 24 : 41-49, 2011
 
29) Chertow GM, Burke SK, Raggi P ; Treat to Goal Working Group : Sevelamer attenuates the progression of coronary artery and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
 
30) Kakuta T, Tanaka R, Hyodo T, et al : Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57 : 422-431, 2011
PubMed
31) Hutchison AJ, Speake M, Al-Baaj F : Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis : a 4-week, dosing, open-label study with lanthanum carbonate. Nephrol Dial Transplant 19 : 1902-1906, 2004
 
32) Al-Baaj F, Speake M, Huchison AJ : Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 20 : 775-782, 2005
 
33) Kawanishi H, Ishida M, Ishizaki M, et al : Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD. Perit Dial Int 28 : 673-682, 2008
PubMed
34) Slatopolsky E, LiaPs H, Finch J : Progressive accumulation of lanthanum in the liver of normal and ureic rats. Kidney Int 68 : 2809-2813, 2005
 
35) Behets GJ, Verberckmoes SC, Oste L, et al : Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67 : 1830-1836, 2005
PubMed
36) Namagondlu G, main N, Yates L, et al : Lanthanum associated abnormal liver function tests in two patients on dialysis : a case report. J Med Case Reports 3 : 932-9324, 2009
 
37) Davis RL, Abraham JL : Lanthanum deposition in a dialysis patient. Nephrol Dial Transplant 24 : 3247-3250, 2009
 
38) Urena P, Vrnejoul MC : Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55 : 2141-2156, 1999
 
39) Yamada S, lnaba M, Kurajoh M, et al : Utility of serum tartrate-resistant acid phosphatase (TRACP 5b) as a bone resorption marker in patients with chronic kidney disease : independence from renal dysfunction. Clin Endocrinol 69 : 189-196, 2008
 
40) Barreto FC, Barreto DV, Moyses RM, et al : K/DOQI recommended serum PHT level do not prevent low turnover bone in hemodialysis patients. Kidney Int 73 : 771-777, 2008
 
41) Sherrard DJ, Hercz G, Pei Y, et al : The spectrum of bone disease in end stage renal failure-an evolving disorder. Kidney Int 43 : 436-442, 1993
PubMed
42) Kazama JJ : Japanese Society of Dialysis Therapy treatment guideiine for secondary hyperparathyroidism. Ther Apher Dial 11 (Suppl 1) : S44-S47, 2007
 
43) Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy ; Japanese Society for Dialysis Therapy : 200g Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. Ther Apher Dial 14 : 489-504, 2010
 
P.75 掲載の参考文献
1) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity inmaintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
2) Guerin AP, London GM, Marchais SJ, et al : Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000
PubMed
3) Blacher J, Guerin AP, Pannier B, et al : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 : 938-942, 2001
PubMed
4) Guorin AP, London GM, Marchais SJ, et al : Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 : 1014-1021, 2000
 
5) Kushihata S, Yorioka N : Effect of H2-blockers on serum calcium and phosphorus in hemodialysis patients on calcium carbonate therapy. ClinNephrol 50 : 198-199, 1998
PubMed
6) Takahashi N, Shoji T, Matsubara K, et al : Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carborlate and calcium lactate in hemodialysis patients. J Am Soc Nephrol 10 : 1090-1094, 1999
PubMed
7) Tan CC, Harden PN, Rodger RS, et al : Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 11 : 851-853, 1996
PubMed
8) Hardy P, Sechet A, Hottelart C, et al : Inhibition of gastric secretion by omeprazole and effciency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 22 : 569-573, 1998
 
9) Matsunaga C, Izumi S, Furukubo T, et al : Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin. Nephrol 68 : 93-98, 2007
PubMed
10) SatohM, Izumi S, Koizumi A, et al : Improvement of hyperphosphatemia following patient educationJ pharmacy Tech 25 : 3-9, 2009
 
11) Chertow GM, Burke SK, Raggi P : Treat to Goal Working Group : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 : 245-252, 2002
 
12) Block GA, Spiegel DM, Ehrlich J, et al : Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 : 1815-1824, 2005
PubMed
13) 西原舞, 平田純生, 和泉智, 他 : 血液透析患者における虚血性腸炎の発症因子に関する検討. 透析会誌 38 : 1279-1283, 2005
 
14) 平田純生, 和泉智, 古久保拓, 他 : 塩酸セベラマー投与による便秘発症予防のための下剤併用法の検討. 透析会誌 37 : 1967-1973, 2004
 
15) Shigematsu T ; Lanthanum Carbonate Group : Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol 70 : 404-410, 2008
PubMed
16) Navaneethan SD, Palmer SC, Craig JC, et al : Benefits and harms of phosphate binders in CKD : a systematic review of randomized controlled trials. Am J Kidney Dis 54 : 619-637, 2009
PubMed
17) 日本薬学会編 : 衛生試験法・要説2005年版. 金原出版, 東京, p381, 2005
 
18) 風間順一郎 : 炭酸Laは安全か? CLINICAL CALCIUM 19 : 224-228, 2009
 
19) Hutchinton AJ : Lanthanum and phosphate : science, policy, and survival. Kidney Int 75 : 355-357, 2009
 
20) Damment SJP, Pennick M : Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 47 : 553-563, 2008
PubMed
21) Hutchison AJ, Barnett ME, Krause RJ, et al ; Lanthanum Carbonate Study Group. : Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 71 : 286-295, 2009
 
22) Bervoets AR, Behets GJ, Schryvers D, et al : Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney Int 75 : 389-398, 2009
PubMed
23) Yang Z, Schryvers D, Roels F, et al : Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 223 : 133-139, 2006
PubMed
24) Daimon T : Toxic Effects of Aluminum on Bone FormationJ Hard TisseBiol 12 : 44-48, 2003
 
25) Pennick M, Dennis K, Damment SJ : Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 46 : 738-746, 2006
PubMed
26) バイエル薬品株式会社 : ホスレノールチュアブル錠250mg/ホスレノールチュアブル錠500mg医薬品. インタビューフォーム, 2010
 
27) Muller C, Chantrel F, Faller B : A confusional state associated with use of lanthanum carbonate in a dialysis patient : a case report. Nephrol Dial Transplant 24 : 3245-3247, 2009
 
28) Fraile P, Cacharro LM, Garcia-Cosmes P, et al : Encephalopathy caused by lanthanum carbonate. NDT Plus 4 : 192-194, 2011
PubMed
29) Altmann P, Barnett ME, Finn WF ; SPD405-307 Lanthanum Carbonate Study Group : Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis : no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 71 : 252-259, 2007
 
30) Damment SJp, Pennick M : Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. ClinPharmacokinet 47 : 553-563, 2008
PubMed
31) Damment SJ, Cox AG, Secker R : Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate ; brain deposition is a contamination artefact? Toxicol lett 188 : 223-229, 2009
PubMed
32) Autissier V, Damment SJ, Henderson RA : Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochlorideJ pharmaceutSci 96 : 2818-2827, 2007
PubMed
33) Shigematsu T : Lanthanum Carbonate Research Group : One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. TherApher Dial 14 : 12-19, 2010
 
34) Bronner F, Slepchenko BM, Pennick M, et al : A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. ClinPharmacokinet 47 : 543-552, 2008
 
35) Persy VP, Benets GJ, Bervoets AR, et al : Lanthanum : asafe phosphate binder. Semin Dial 19 : 195-199, 2006
 
36) Hutchison AJ, Barnett ME, Krause R, et al : Long-term efficacy and safety profile of lanthanum carbonate : results for up to 6 years of treatment. Nephron Clin Pract 110 : c15-23, 2008
PubMed
37) Behets GJ, Dams G, Vercauteren SR, et al : Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? Jam Soc Nephrol 15 : 2219-2228, 2004
 
P.86 掲載の参考文献
1) Moe S, Drueke T, Cunningham J, et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Shoji T, Shinohara K, Kimoto E, et al : Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19 : 179-184, 2004
 
3) Teng M, Wolf M, Ofsthun MN, et al : Activated injectable vitamin D and hemodialysis survival : a historical cohort study. J Am Soc Nephrol 16 : 1115-1125, 2005
PubMed
4) Block GA, Klassen PS, Lazarus JM, et al : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 : 2208-2218, 2004
PubMed
5) Nakai S, Akiba T, Kazama J, et al : Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12 : 49-54, 2008
PubMed
6) 日本透析医学会 : わが国の慢性透析療法の現況 (1998年12月31日現在). 東京, 日本透析医学会, 1999, pp 622-624
 
7) Kalantar-Zadeh K, Kuwae N, Regidor DL, et al : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 : 771-780, 2006
PubMed
8) Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al : Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74 : 1070-1078, 2008
PubMed
9) Shinaberger CS, KoPPIe JD, Kovesdy CP, et al : Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 3 : 1769-1776, 2008
 
10) Teng M, Wolf M, Lowrie E, et al : Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 : 446-456, 2003
PubMed
11) Tentori F, Hunt WC, Stidley CA, et al : Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70 : 1858-1865, 2006
PubMed
12) Melamed ML, Eustace JA, Plantinga L, et al : Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients : a longitudinal study. Kidney Int 70 : 351-357, 2006
PubMed
13) Wolf M, Shah A, Gutierrez O, et al : Vitamin D levels and early mortality among incident hemodialysis patients, Kidney Int 72 : 1004-1013, 2007
PubMed
14) Wang AY, Lam CW, Sanderson JE, et al : Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients : a 3-y prospective cohort study. Am J Clin Nutr 87 : 1631-1638, 2008
PubMed
15) Tentori F, Albert JM, Young EW, et al : The survival advantage for haemodialysis patients taking vitamin D is questioned : findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24 : 963-972, 2009
PubMed
16) Nishizawa Y, Shoji T, Ishimura E, et al : Paradox of risk factors for cardiovascular mortality in uremia : is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 38 : S4-7, 2001
PubMed
17) Shoji T, Nishizawa Y : Chronic kidney disease as a metabolic syndrome with malnutrition-need for strict control of risk factors. Intern Med 44 : 179-187, 2005
PubMed
18) Shoji T, Tsubakihara Y, Nakai S, et al : Reverse epidemiology in hemodialysis patients. Lessons from Japanese registries. Nephrol Ther 4 : 223-227, 2008
PubMed
19) Shoji T, Masakane I, Watanabe Y, et al : Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6 : 1112-1120, 2011
PubMed
20) Kimoto E, Shoji T, Shinohara K, et al : Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 17 : 2245-2252, 2006
PubMed
21) Marz W, Genser B, Drechsler C, et al : Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6 : 1316-1325, 2011
PubMed
22) Kovesdy CP, Kalantar-Zadeh K : Vitamin D receptor activation and survival in chronic Kidney disease. Kidney int 73 : 1355-1363, 2008
PubMed
23) Manenti L, Vaglio A, Pasquali S : Increased fetuin-A levels following treatment with a vitamin D analog. Kidney Int 78 : 1187 ; author reply 1187-1189, 2010
PubMed
24) de Zeeuw D, Agarwal R, Amdahl M, et al : Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) : a randomised controlled trial. Lancet 376 : 1543-1551, 2011
 
25) Kim MJ, Frankel AH, Donaldson M, et al : Oral cholecalciferol decreases albuminuria and urinary TGF-betal in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 80 : 851-860, 2011
 
26) Shigematsu T : Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol 14 : 589-597, 2010
PubMed
27) Shigematsu T : One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 14 : 12-19, 2010
PubMed
28) Pierce D, Hossack S, Poole L, et al : The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant 26 : 1615-1621, 2011
PubMed
P.94 掲載の参考文献
1) Shigematsu T : the Lanthanum Carbonate Research Group : One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis. Ther Apher Dial 14 : 12-19, 2009
 
2) 鈴木大介, 内田将吾, 中村紗知, 他 : セベラマー塩酸塩から炭酸ランタンへの切り替えによる経時的消化器症状調査. 日病薬誌 46 : 919-923, 2010
 
3) Cerny S, Kunzendorf U : Radiographic appearance of lanthanum. N Engl J Med 355 : 1160, 2006
PubMed
4) Chuang CL, Shiou SY, Li SY, et al : Aperitoneal dialysis patients with an unusual abdominal film. Kidney Int 72 : 1291, 2007
 
5) Muller C, Chantrel E Faller B : A confusional state associated with use of lanthanum carbonate in a dialysis patients : a case report. Nephrol Dial Transplant 24 : 3245, 2009
 
6) 森慶太, 越川真男, 明石健吾, 他 : 炭酸ランタンの腸管内遺残を認めた血液透析患者の1例. 透析会誌 43 : 853-857, 2010
 
7) 北田博久 : 炭酸ランタンによる高リン血症治療-チュアブル錠適正使用の服薬指導によりリン低下効果が改善した症例-. 医学と薬学 64 : 69-74, 2010
Medical*Online
8) Kato A, Takita T, Furuhashi M : Accumulation of lanthanum carbonate in the digestive tracts. Clin Exp Nephrol 14 : 100-101, 2010
PubMed
9) Furstenberg A, Buscombe J, Davenport A : Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease. Am J Nephrol 32 : 425-431, 2010
 
P.100 掲載の参考文献
1) Kidney Disease : Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Collaborators KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 113 (Suppl) : S1-130, 2009
 
2) Massry S : K/DOQI CIinical Practice Guidelines : Am J Kidney Dis 42 (Suppl 3) : S1-201, 2003
 
3) 日本透析医学会 : 透析患者における二次性副甲状腺機能亢進症治療ガイドライン. 透析会誌 39 : 1435-1455, 2006
 
4) Levin A, Bakris GL, Molitch M, et al : Prev alence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease : results of the study to evaluate early kidney disease. Kidney Int 71 : 31-38, 2007
 
5) Russo D, Corrao S, Miranda I, et al : Progression of coronary artery calcification in predialysis patients. Am J Nephrol 27 : 152-158, 2007
PubMed
6) Adeney KL, Siscovick DS, Ix JH, et al : Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20 : 381-387, 2008
PubMed
7) Ix JH, De Boer IH, Peralta CA, et al : Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 4 : 609-615, 2009
PubMed
8) Levin A, Djurdjev O, Beaulieu M, et al : Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis : 661-671, 2008
 
9) Schwarz S, Trivedi BK, Kalantar-Zadeh K, et al : Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1 : 825-831, 2006
PubMed
10) Tonelli M, Sacks F, Pfeffer M, et al : Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112 : 2627-2633, 2005
PubMed
11) Tonelli M, Curhan G, Pfeffer M, et al : Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 120 : 1784-1792, 2009
PubMed
12) Abramowitz M, Muntner P, Coco M, et al : Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol 5 : 1064-1071, 2010
PubMed
13) Eddington H, Hoefield R, Sinha S, et al : Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5 : 2251-2257, 2010
PubMed
14) Kestenbaum B, Sampson JN, Rudser KD, et al : Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 : 520-528, 2005
PubMed
15) Menon V, Greene T, Pereira AA, et al : Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 46 : 455-463, 2005
PubMed
16) Kovesdy CP, Ahmadzadeh S, Anderson JE, et al : Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73 : 1296-1302, 2008
PubMed
17) Kovesdy CP, Anderson JE, Kalantar-zadeh K : Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol 73 : 268-275, 2010
PubMed
18) Kovesdy CP, Ureche V, Lu JL, et al : Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 25 : 3003-3011, 2010
PubMed
19) Kovesdy CP, Kuchmak O, Lu JL, et al : Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 56 : 842-851, 2010
PubMed
20) Russo D, Miranda I, Ruocco C, et al : The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72 : 1255-1261, 2007
PubMed
21) Tonelli M, Pannu N, Manns B : Oral phosphate binders in patients with kidney failure. N Engl J Med 362 : 1312-1324, 2010
PubMed
22) Sprague SM, Abboud H, Qiu P, et al : Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4 : a randomized trial. Clin J Am Soc Nephrol : 178-185, 2009
PubMed
23) Date T, Shigematsu T, Kawashita Y, et al : Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 18 : iii90-93, 2003
PubMed
24) Tzanakis I, Pras A, Kounali D, et al : Mitral annular calcifications in haemodialysis patients : a possible protective role of magnesium. Nephrol Dial Transplant 12 : 2036-2037, 1997
PubMed
25) Ishimura E, Okuno S, Kitatani K, et al : Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 68 : 222-227, 2007
PubMed
26) Ishimura E, Okuno S, Yamakawa T, et al : Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 20 : 237-244, 2007
PubMed
27) Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J : Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 22 : 37-44, 2009
PubMed
28) Kanbay M, Goldsmith D, Uyar ME, et al : Magnesium in chronic kidney disease : challenges and opportunities. Blood Purif 1-13, 2009
 
29) Meema HE, Oreopoulos DG, Rapoport A : Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 32 : 388-394, 1987
PubMed
30) de Francisco AL, Leidig M, Covic AC, et al : Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients : a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 25 : 3707-3717, 2010
PubMed
31) Mclntyre CW, Pai P, Warwick G, et al : Iron-magnesium hydroxycarbonate (fermagate) : a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 4 : 401-409, 2009
 
32) Block GA, Brillhart SL, Persky MS, et al : Efficacy and safety of SBR759, a new ironbased phosphate binder. Kidney Int 77 : 897-903, 2010
PubMed

書評

最近チェックした商品履歴

Loading...